November 18, 2016

Long-Term Analysis of All 695 Patients Enrolled in Novocure’s Phase 3 Pivotal Trial in Newly Diagnosed Glioblastoma Confirms Successful Interim Analysis Results and Demonstrates Superior Two- and Four-Year Survival Rates

Patients treated with Optune® together with temozolomide demonstrated a significant increase in progression free and overall survival compared to patients treated with temozolomide alone Patients treated with Optune® together with temozolomide demonstrated a significant increase in progression free and overall survival compared to patients treated with temozolomide… Read More
learn more
November 18, 2016

Long-Term Analysis of All 695 Patients Enrolled in Novocure’s Phase 3 Pivotal Trial in Newly Diagnosed Glioblastoma Confirms Successful Interim Analysis Results and Demonstrates Superior Two- and Four-Year Survival Rates

Patients treated with Optune® together with temozolomide demonstrated a significant increase in progression free and overall survival compared to patients treated with temozolomide alone Patients treated with Optune® together with temozolomide demonstrated a significant increase in progression free and overall survival compared to patients treated with temozolomide… Read More
learn more
November 18, 2016

Long-Term Analysis of All 695 Patients Enrolled in Novocure’s Phase 3 Pivotal Trial in Newly Diagnosed Glioblastoma Confirms Successful Interim Analysis Results and Demonstrates Superior Two- and Four-Year Survival Rates

Patients treated with Optune® together with temozolomide demonstrated a significant increase in progression free and overall survival compared to patients treated with temozolomide alone Patients treated with Optune® together with temozolomide demonstrated a significant increase in progression free and overall survival compared to patients treated with temozolomide… Read More
learn more
November 17, 2016

Novocure Presents Interim STELLAR Results at IASLC Suggesting Treatment with Tumor Treating Fields Plus Chemotherapy may Extend Survival of Patients with Mesothelioma

One-year survival rates of patients treated with Tumor Treating Fields combined with pemetrexed and cisplatin or carboplatin were more than 58% greater than historical control data One-year survival rates of patients treated with Tumor Treating Fields combined with pemetrexed and cisplatin or carboplatin were more than 58%… Read More
learn more
November 17, 2016

Novocure Presents Interim STELLAR Results at IASLC Suggesting Treatment with Tumor Treating Fields Plus Chemotherapy may Extend Survival of Patients with Mesothelioma

One-year survival rates of patients treated with Tumor Treating Fields combined with pemetrexed and cisplatin or carboplatin were more than 58% greater than historical control data One-year survival rates of patients treated with Tumor Treating Fields combined with pemetrexed and cisplatin or carboplatin were more than 58%… Read More
learn more
November 17, 2016

Novocure Presents Interim STELLAR Results at IASLC Suggesting Treatment with Tumor Treating Fields Plus Chemotherapy may Extend Survival of Patients with Mesothelioma

One-year survival rates of patients treated with Tumor Treating Fields combined with pemetrexed and cisplatin or carboplatin were more than 58% greater than historical control data One-year survival rates of patients treated with Tumor Treating Fields combined with pemetrexed and cisplatin or carboplatin were more than 58%… Read More
learn more
November 14, 2016

Novocure Sponsors Pulitzer Prize-Winning Author Dr. Siddhartha Mukherjee as Keynote Speaker of 21st Annual Scientific Meeting of the Society for Neuro-Oncology

Dr. Mukherjee wrote Pulitzer Prize-Winning book The Emperor of All Maladies and New York Times bestseller The Gene. Dr. Mukherjee wrote Pulitzer Prize-Winning book The Emperor of All Maladies and New York Times bestseller The Gene. Novocure has sponsored Pulitzer Prize-winning… Read More
learn more
November 14, 2016

Novocure Sponsors Pulitzer Prize-Winning Author Dr. Siddhartha Mukherjee as Keynote Speaker of 21st Annual Scientific Meeting of the Society for Neuro-Oncology

Dr. Mukherjee wrote Pulitzer Prize-Winning book The Emperor of All Maladies and New York Times bestseller The Gene. Dr. Mukherjee wrote Pulitzer Prize-Winning book The Emperor of All Maladies and New York Times bestseller The Gene. Novocure has sponsored Pulitzer Prize-winning… Read More
learn more
November 14, 2016

Novocure Sponsors Pulitzer Prize-Winning Author Dr. Siddhartha Mukherjee as Keynote Speaker of 21st Annual Scientific Meeting of the Society for Neuro-Oncology

Dr. Mukherjee wrote Pulitzer Prize-Winning book The Emperor of All Maladies and New York Times bestseller The Gene. Dr. Mukherjee wrote Pulitzer Prize-Winning book The Emperor of All Maladies and New York Times bestseller The Gene. Novocure has sponsored Pulitzer Prize-winning… Read More
learn more
November 7, 2016

Novocure Announces 38 Presentations on Tumor Treating Fields at 21st Annual Scientific Meeting of the Society of Neuro-Oncology

28 of 38 abstracts were prepared by external researchers, representing increasing interest in Novocure’s proprietary therapy 28 of 38 abstracts were prepared by external researchers, representing increasing interest in Novocure’s proprietary therapy The long-term analysis of all 695 patients enrolled in its phase 3… Read More
learn more